Literature DB >> 25569262

Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

R Herrero1, L M Real2, A Rivero-Juárez3, J A Pineda2, Á Camacho3, J Macías2, M Laplana4, P Konieczny1, F J Márquez1, J C Souto5, J M Soria5, I Saulle6, S Lo Caputo7, M Biasin6, A Rivero3, J Fibla4, A Caruz1.   

Abstract

HIV-1 induces activation of complement through the classical and lectin pathways. However, the virus incorporates several membrane-bound or soluble regulators of complement activation (RCA) that inactivate complement. HIV-1 can also use the complement receptors (CRs) for complement-mediated antibody-dependent enhancement of infection (Ć-ADE). We hypothesize that hypofunctional polymorphisms in RCA or CRs may protect from HIV-1 infection. For this purpose, 139 SNPs located in 19 RCA and CRs genes were genotyped in a population of 201 Spanish HIV-1-exposed seronegative individuals (HESN) and 250 HIV-1-infected patients. Two SNPs were associated with infection susceptibility, rs1567190 in CR2 (odds ratio (OR) = 2.27, P = 1 × 10(-4)) and rs2842704 in C4BPA (OR = 2.11, P = 2 × 10(-4)). To replicate this finding, we analyzed a cohort of Italian, sexually HESN individuals. Although not significant (P = 0.25, OR = 1.57), similar genotypic proportions were obtained for the CR2 marker rs1567190. The results of the two association analyses were combined through a random effect meta-analysis, with a significant P-value of 2.6 x 10(-5) (OR = 2.07). Furthermore, we found that the protective CR2 genotype is correlated with lower levels CR2 mRNA as well as differences in the ratio of the long and short CR2 isoforms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25569262     DOI: 10.1038/gene.2014.71

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  41 in total

1.  A common polymorphism in TLR3 confers natural resistance to HIV-1 infection.

Authors:  Manuela Sironi; Mara Biasin; Rachele Cagliani; Diego Forni; Mariacristina De Luca; Irma Saulle; Sergio Lo Caputo; Francesco Mazzotta; Juan Macías; Juan A Pineda; Antonio Caruz; Mario Clerici
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

Review 2.  HIV and human complement: inefficient virolysis and effective adherence.

Authors:  Zoltán Bánki; Heribert Stoiber; Manfred P Dierich
Journal:  Immunol Lett       Date:  2004-11-28       Impact factor: 3.685

Review 3.  Emerging role for complement in HIV infection.

Authors:  Georg Huber; Zoltán Bánki; Susanne Lengauer; Heribert Stoiber
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

4.  The effects of oestrogen administration on the plasma free protein S and C4b-binding protein.

Authors:  E Melissari; V V Kakkar
Journal:  Thromb Res       Date:  1988-03-01       Impact factor: 3.944

5.  Functional and immunologic protein S levels are decreased during pregnancy.

Authors:  P C Comp; G R Thurnau; J Welsh; C T Esmon
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

Review 6.  Sex affects immunity.

Authors:  Leesa M Pennell; Carole L Galligan; Eleanor N Fish
Journal:  J Autoimmun       Date:  2012-01-04       Impact factor: 7.094

Review 7.  Mannose binding lectin (MBL) and HIV.

Authors:  Xin Ji; Henry Gewurz; Gregory T Spear
Journal:  Mol Immunol       Date:  2005-02       Impact factor: 4.407

8.  Binding of complement inhibitor C4b-binding protein to a highly virulent Streptococcus pyogenes M1 strain is mediated by protein H and enhances adhesion to and invasion of endothelial cells.

Authors:  David Ermert; Antonin Weckel; Vaibhav Agarwal; Inga-Maria Frick; Lars Björck; Anna M Blom
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

9.  Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus.

Authors:  Hui Wu; Susan A Boackle; Punchong Hanvivadhanakul; Daniela Ulgiati; Jennifer M Grossman; Youngho Lee; Nan Shen; Lawrence J Abraham; Timothy R Mercer; Elly Park; Lee A Hebert; Brad H Rovin; Dan J Birmingham; Deh-Ming Chang; Chung Jen Chen; Deborah McCurdy; Humeira M Badsha; Bernard Y H Thong; Hiok H Chng; Frank C Arnett; Daniel J Wallace; C Yung Yu; Bevra H Hahn; Rita M Cantor; Betty P Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-22       Impact factor: 11.205

10.  Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing.

Authors:  K B Douglas; D C Windels; J Zhao; A V Gadeliya; H Wu; K M Kaufman; J B Harley; J Merrill; R P Kimberly; G S Alarcón; E E Brown; J C Edberg; R Ramsey-Goldman; M Petri; J D Reveille; L M Vilá; P M Gaffney; J A James; K L Moser; M E Alarcón-Riquelme; T J Vyse; G S Gilkeson; C O Jacob; J T Ziegler; C D Langefeld; D Ulgiati; B P Tsao; S A Boackle
Journal:  Genes Immun       Date:  2009-04-23       Impact factor: 2.676

View more
  3 in total

1.  Choriodecidual leukocytes display a unique gene expression signature in spontaneous labor at term.

Authors:  Marcia Arenas-Hernandez; Nardhy Gomez-Lopez; Valeria Garcia-Flores; Claudia Rangel-Escareño; Luis M Alvarez-Salas; Natalia Martinez-Acuña; Joel A Vazquez-Perez; Rodrigo Vega-Sanchez
Journal:  Genes Immun       Date:  2018-01-24       Impact factor: 2.676

2.  CD46 Genetic Variability and HIV-1 Infection Susceptibility.

Authors:  Carmen Serrano-Rísquez; Mohamed Omar; María Amparo Gómez-Vidal; Luis Miguel Real; Juan Antonio Pineda; Antonio Rivero; Antonio Rivero-Juárez; Donald Forthal; Francisco J Márquez; Sergio Lo Caputo; Mario Clerici; Mara Biasin; Antonio Caruz
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

3.  Enhanced Signaling Through the TLR9 Pathway Is Associated With Resistance to HIV-1 Infection in Chinese HIV-1-Exposed Seronegative Individuals.

Authors:  Junjun Jiang; Xi Hu; Wenwei Li; Jie Liu; Bingyu Liang; Hui Chen; Jiegang Huang; Ning Zang; Chuanyi Ning; Yanyan Liao; Rongfeng Chen; Jingzhen Lai; Jiemei Chu; Peijiang Pan; Ping Cui; Qiao Tang; Xiu Chen; Hao Liang; Li Ye
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.